LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article ; Online: Evaluating rates of reporting symptoms of Parkinson's disease psychosis: provider versus targeted questionnaire.

    Greger, Jessica / Aladeen, Traci / Rainka, Michelle / Kale, Anupama / Capote, Horacio

    The International journal of neuroscience

    2020  Volume 132, Issue 5, Page(s) 459–465

    Abstract: Purpose/aim: A targeted questionnaire may help increase rates of reporting Parkinson's disease psychosis (PDP) symptoms. Despite the need for a rapid patient- and/or caregiver-administered screening tool for PDP symptoms, an appropriate tool is not yet ... ...

    Abstract Purpose/aim: A targeted questionnaire may help increase rates of reporting Parkinson's disease psychosis (PDP) symptoms. Despite the need for a rapid patient- and/or caregiver-administered screening tool for PDP symptoms, an appropriate tool is not yet available. This study developed a targeted PDP questionnaire and examined rates of reporting psychosis symptoms in response to the questionnaire compared to rates of reporting symptoms to healthcare providers during a routine visit.
    Materials and methods: This was a single-center, cross-sectional observational study of patients at an outpatient neurology practice. Medical charts were screened for eligibility, and patients were contacted by telephone for informed consent.
    Results: A total of 25 patients (24%,
    Conclusions: A targeted questionnaire increases rates of reporting PDP symptoms, and based on frequency, severity, and distress ratings, may allow for capture of PDP symptoms earlier in the course of the disease. By using a questionnaire, patients reported symptom onset an average of 1.4 years earlier than patients who reported symptoms to their providers according to patient medical records.
    MeSH term(s) Cross-Sectional Studies ; Humans ; Parkinson Disease/complications ; Parkinson Disease/diagnosis ; Parkinson Disease/epidemiology ; Psychotic Disorders/diagnosis ; Psychotic Disorders/epidemiology ; Surveys and Questionnaires
    Language English
    Publishing date 2020-09-22
    Publishing country England
    Document type Journal Article ; Observational Study
    ZDB-ID 3061-2
    ISSN 1563-5279 ; 1543-5245 ; 0020-7454
    ISSN (online) 1563-5279 ; 1543-5245
    ISSN 0020-7454
    DOI 10.1080/00207454.2020.1821678
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Neuroimaging in psychiatry.

    Capote, Horacio A

    Neurologic clinics

    2009  Volume 27, Issue 1, Page(s) 237–49, x

    Abstract: Psychiatric neuroimaging has made great strides. PET scanning to differentiate between the dementias is clinically useful and well accepted. Understanding of the pathophysiology underlying the psychopathology of psychiatric illness also is rapidly ... ...

    Abstract Psychiatric neuroimaging has made great strides. PET scanning to differentiate between the dementias is clinically useful and well accepted. Understanding of the pathophysiology underlying the psychopathology of psychiatric illness also is rapidly expanding. Neuroimaging quickly is becoming an indispensable part of the day-to-day clinical management of psychiatric patients.
    MeSH term(s) Brain/pathology ; Diagnostic Imaging/methods ; Humans ; Mental Disorders/diagnosis ; Mental Disorders/therapy ; Psychiatry
    Language English
    Publishing date 2009-02
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 1013148-6
    ISSN 1557-9875 ; 0733-8619
    ISSN (online) 1557-9875
    ISSN 0733-8619
    DOI 10.1016/j.ncl.2008.09.011
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Comparison of the Metabolic Characteristics of Newer Second Generation Antipsychotics: Brexpiprazole, Lurasidone, Asenapine, Cariprazine, and Iloperidone With Olanzapine as a Comparator.

    Greger, Jessica / Aladeen, Traci / Lewandowski, Emily / Wojcik, Rachael / Westphal, Erica / Rainka, Michelle / Capote, Horacio

    Journal of clinical psychopharmacology

    2020  Volume 41, Issue 1, Page(s) 5–12

    Abstract: Purpose/background: Extensive research has been conducted comparing the metabolic characteristics of older second-generation antipsychotics (SGAs); minimal data exist comparing the long-term metabolic effects of SGAs approved in the last 10 years.: ... ...

    Abstract Purpose/background: Extensive research has been conducted comparing the metabolic characteristics of older second-generation antipsychotics (SGAs); minimal data exist comparing the long-term metabolic effects of SGAs approved in the last 10 years.
    Methods/procedures: A retrospective chart review of patients treated with brexpiprazole, lurasidone, asenapine, cariprazine, and iloperidone (newer SGAs) for at least 6 weeks at an outpatient psychiatric practice was conducted. Patients treated with olanzapine, an older SGA, were included as a comparator. Metabolic characteristics were collected at baseline, approximately 6 weeks, 12 weeks, and for up to 12 months.
    Findings/results: Of the newer SGAs, there were statistically significant increases in patients' average weight at 12 weeks and 1 year or less with brexpiprazole (2.48 lb, P = 0.02; 5.97 lb, P = 0.01) and iloperidone (4.54 lb, P < 0.01; 5.13 lb, P = 0.02). Brexpiprazole and iloperidone resulted in significant increases in body mass index, up to a 0.90-kg/m2 average increase in patients taking brexpiprazole at 1 year or less. Minimal weight gain was seen with cariprazine (4.25 lb, P = 0.42) and asenapine (1.80 lb, P = 0.62) at 1 year or less after treatment initiation. Although not statistically significant, lurasidone showed an average weight loss of up to 0.60 lb at 1 year or less (P = 0.56).
    Implications/conclusions: Although some weight gain was seen with the newer SGAs, all demonstrated significantly favorable metabolic characteristics compared with olanzapine. Monitoring of weight and metabolic parameters remain important in patients treated with SGAs.
    MeSH term(s) Adult ; Aged ; Antipsychotic Agents/adverse effects ; Antipsychotic Agents/therapeutic use ; Bipolar Disorder/drug therapy ; Blood Pressure/drug effects ; Dibenzocycloheptenes/adverse effects ; Female ; Humans ; Isoxazoles/adverse effects ; Lurasidone Hydrochloride/adverse effects ; Male ; Middle Aged ; Olanzapine/adverse effects ; Piperazines/adverse effects ; Piperidines/adverse effects ; Quinolones/adverse effects ; Retrospective Studies ; Thiophenes/adverse effects ; Weight Gain/drug effects
    Chemical Substances Antipsychotic Agents ; Dibenzocycloheptenes ; Isoxazoles ; Piperazines ; Piperidines ; Quinolones ; Thiophenes ; brexpiprazole (2J3YBM1K8C) ; cariprazine (F6RJL8B278) ; asenapine (JKZ19V908O) ; Olanzapine (N7U69T4SZR) ; Lurasidone Hydrochloride (O0P4I5851I) ; iloperidone (VPO7KJ050N)
    Language English
    Publishing date 2020-11-24
    Publishing country United States
    Document type Journal Article
    ZDB-ID 604631-9
    ISSN 1533-712X ; 0271-0749
    ISSN (online) 1533-712X
    ISSN 0271-0749
    DOI 10.1097/JCP.0000000000001318
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: L-Methylfolate Calcium Supplementation in Adolescents and Children: A Retrospective Analysis.

    Rainka, Michelle / Aladeen, Traci / Westphal, Erica / Meaney, Jacqueline / Gengo, Fran / Greger, Jessica / Capote, Horacio

    Journal of psychiatric practice

    2019  Volume 25, Issue 4, Page(s) 258–267

    Abstract: Previous studies have shown l-methylfolate to be a safe and beneficial therapy for neuropsychiatric conditions, including major depressive disorder and schizophrenia in adults. The purpose of this study was to assess safety and describe patient ... ...

    Abstract Previous studies have shown l-methylfolate to be a safe and beneficial therapy for neuropsychiatric conditions, including major depressive disorder and schizophrenia in adults. The purpose of this study was to assess safety and describe patient experience using l-methylfolate calcium in a real-world pediatric and adolescent population. A retrospective chart review of patients (7 to 20 y of age, mean age 16 y) prescribed l-methylfolate calcium at a psychiatry clinic in Amherst, NY, between January 1, 2010 and November 10, 2015 was conducted. Patients to whom l-methylfolate calcium 15 mg/d (n=139) or 7.5 mg/d (n=7) was administered were identified; 44 patients who were prescribed but to whom l-methylfolate calcium was not administered were included as a comparator population. Common neuropsychiatric diagnoses included anxiety disorders (68% in the treatment population vs. 50% in the comparator population) and mood disorders (57% in the treatment population vs. 52% in the comparator population). Antidepressants (69% vs. 55%) and mood stabilizers or antiepileptic drugs (63% vs. 57%) were frequently prescribed in combination with l-methylfolate calcium. Adverse events occurred less frequently in the treated population, possibly due to the addition of l-methylfolate calcium (10% vs. 25%, P=0.02). The most common adverse events in the treated population were impaired sleep (5 patients) and increased anxiety (3 patients). Rates of laboratory abnormalities did not differ significantly between the treated and comparator populations (P=0.13). Positive subjective treatment experiences were reported by 22.5% of treated patients and negative subjective treatment experiences were reported by 5.4% of treated patients. L-methylfolate calcium was well-tolerated in a pediatric/adolescent population and may provide benefits for patients with a range of neuropsychiatric conditions.
    MeSH term(s) Adolescent ; Anticonvulsants/administration & dosage ; Anticonvulsants/therapeutic use ; Antidepressive Agents/administration & dosage ; Antidepressive Agents/therapeutic use ; Anxiety Disorders/drug therapy ; Child ; Drug Therapy, Combination ; Female ; Humans ; Male ; Mental Disorders/drug therapy ; Mood Disorders/drug therapy ; Retrospective Studies ; Tetrahydrofolates/administration & dosage ; Tetrahydrofolates/therapeutic use ; Young Adult
    Chemical Substances Anticonvulsants ; Antidepressive Agents ; Tetrahydrofolates ; 5-methyltetrahydrofolate (TYK22LML8F)
    Language English
    Publishing date 2019-05-31
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2022726-7
    ISSN 1538-1145 ; 1527-4160
    ISSN (online) 1538-1145
    ISSN 1527-4160
    DOI 10.1097/PRA.0000000000000400
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Ropinirole in Bipolar Disorder: Rate of Manic Switching and Change in Disease Severity.

    Capote, Horacio A / Rainka, Michelle / Westphal, Erica S / Beecher, Jonathan / Gengo, Francis M

    Perspectives in psychiatric care

    2017  Volume 54, Issue 2, Page(s) 100–106

    Abstract: Purpose: To determine the effects of ropinirole on manic switching and disease severity in bipolar disorder.: Design and methods: A cross-sectional survey was conducted in 23 bipolar depressed patients using ropinirole combination therapy (Young ... ...

    Abstract Purpose: To determine the effects of ropinirole on manic switching and disease severity in bipolar disorder.
    Design and methods: A cross-sectional survey was conducted in 23 bipolar depressed patients using ropinirole combination therapy (Young Mania Rating Scale [YMRS], Bipolar Inventory of Symptoms Scale [BISS]). Retrospective Clinical Global Impression of Change (CGI-C) and CGI-S (Severity) were captured via chart review.
    Findings: One patient (4.3%) experienced induction of mania (YMRS). All patients responded or partially responded to ropinirole (CGIs). YMRS and BISS mania scores were correlated.
    Practice implications: Ropinirole has a low rate of manic switching and significantly reduces bipolar depression severity.
    MeSH term(s) Adult ; Aged ; Bipolar Disorder/drug therapy ; Cross-Sectional Studies ; Female ; Humans ; Indoles/administration & dosage ; Indoles/adverse effects ; Indoles/pharmacology ; Male ; Middle Aged ; Outcome Assessment (Health Care) ; Severity of Illness Index ; Young Adult
    Chemical Substances Indoles ; ropinirole (030PYR8953)
    Language English
    Publishing date 2017-01-20
    Publishing country United States
    Document type Journal Article
    ZDB-ID 391097-0
    ISSN 1744-6163 ; 0031-5990
    ISSN (online) 1744-6163
    ISSN 0031-5990
    DOI 10.1111/ppc.12205
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: The use of brexpiprazole amongst individuals with insufficient outcomes with aripiprazole or bupropion: A case series.

    Aladeen, Traci / Westphal, Erica / Lee, Yena / Rong, Carola / Rainka, Michelle / Capote, Horacio / McIntyre, Roger S

    Perspectives in psychiatric care

    2018  Volume 54, Issue 4, Page(s) 507–513

    Abstract: Purpose: We sought to characterize the clinical experience of outpatients treated with brexpiprazole after achieving suboptimal outcomes with aripiprazole or bupropion as determined by the treating psychiatric provider.: Design and methods: Case ... ...

    Abstract Purpose: We sought to characterize the clinical experience of outpatients treated with brexpiprazole after achieving suboptimal outcomes with aripiprazole or bupropion as determined by the treating psychiatric provider.
    Design and methods: Case series; inefficacy, intolerability, or other unsatisfactory outcome to previous trial with aripiprazole or bupropion.
    Findings: The majority of individuals in our sample exhibited tolerability of brexpiprazole. In addition, reduction in mean PHQ-9 scores was observed with brexpiprazole treatment.
    Implications: The results of our preliminary analysis suggest that a subpopulation of adults who have insufficient outcomes on aripiprazole or bupropion due to intolerability, inefficacy or other unsatisfactory outcome may benefit by switching to brexpiprazole treatment. Larger randomized controlled trials are needed, as well as sophisticated network analysis to further understand efficacy and tolerability differences between atypical antipsychotics.
    MeSH term(s) Adult ; Antipsychotic Agents/adverse effects ; Antipsychotic Agents/therapeutic use ; Aripiprazole/adverse effects ; Aripiprazole/therapeutic use ; Bupropion/adverse effects ; Bupropion/therapeutic use ; Depressive Disorder, Major/drug therapy ; Female ; Humans ; Male ; Middle Aged ; New York ; Psychiatric Status Rating Scales ; Quinolones/adverse effects ; Quinolones/therapeutic use ; Retrospective Studies ; Thiophenes/adverse effects ; Thiophenes/therapeutic use ; Treatment Outcome ; Young Adult
    Chemical Substances Antipsychotic Agents ; Quinolones ; Thiophenes ; Bupropion (01ZG3TPX31) ; brexpiprazole (2J3YBM1K8C) ; Aripiprazole (82VFR53I78)
    Language English
    Publishing date 2018-02-10
    Publishing country United States
    Document type Journal Article
    ZDB-ID 391097-0
    ISSN 1744-6163 ; 0031-5990
    ISSN (online) 1744-6163
    ISSN 0031-5990
    DOI 10.1111/ppc.12258
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans.

    Bakken, Trygve E / Roddey, J Cooper / Djurovic, Srdjan / Akshoomoff, Natacha / Amaral, David G / Bloss, Cinnamon S / Casey, B J / Chang, Linda / Ernst, Thomas M / Gruen, Jeffrey R / Jernigan, Terry L / Kaufmann, Walter E / Kenet, Tal / Kennedy, David N / Kuperman, Joshua M / Murray, Sarah S / Sowell, Elizabeth R / Rimol, Lars M / Mattingsdal, Morten /
    Melle, Ingrid / Agartz, Ingrid / Andreassen, Ole A / Schork, Nicholas J / Dale, Anders M / Weiner, Michael / Aisen, Paul / Petersen, Ronald / Jack, Clifford R / Jagust, William / Trojanowki, John Q / Toga, Arthur W / Beckett, Laurel / Green, Robert C / Saykin, Andrew J / Morris, John / Liu, Enchi / Montine, Tom / Gamst, Anthony / Thomas, Ronald G / Donohue, Michael / Walter, Sarah / Gessert, Devon / Sather, Tamie / Harvey, Danielle / Kornak, John / Dale, Anders / Bernstein, Matthew / Felmlee, Joel / Fox, Nick / Thompson, Paul / Schuff, Norbert / Alexander, Gene / DeCarli, Charles / Bandy, Dan / Koeppe, Robert A / Foster, Norm / Reiman, Eric M / Chen, Kewei / Mathis, Chet / Cairns, Nigel J / Taylor-Reinwald, Lisa / Trojanowki, J Q / Shaw, Les / Lee, Virginia M Y / Korecka, Magdalena / Crawford, Karen / Neu, Scott / Foroud, Tatiana M / Potkin, Steven / Shen, Li / Kachaturian, Zaven / Frank, Richard / Snyder, Peter J / Molchan, Susan / Kaye, Jeffrey / Quinn, Joseph / Lind, Betty / Dolen, Sara / Schneider, Lon S / Pawluczyk, Sonia / Spann, Bryan M / Brewer, James / Vanderswag, Helen / Heidebrink, Judith L / Lord, Joanne L / Johnson, Kris / Doody, Rachelle S / Villanueva-Meyer, Javier / Chowdhury, Munir / Stern, Yaakov / Honig, Lawrence S / Bell, Karen L / Morris, John C / Ances, Beau / Carroll, Maria / Leon, Sue / Mintun, Mark A / Schneider, Stacy / Marson, Daniel / Griffith, Randall / Clark, David / Grossman, Hillel / Mitsis, Effie / Romirowsky, Aliza / deToledo-Morrell, Leyla / Shah, Raj C / Duara, Ranjan / Varon, Daniel / Roberts, Peggy / Albert, Marilyn / Onyike, Chiadi / Kielb, Stephanie / Rusinek, Henry / de Leon, Mony J / Glodzik, Lidia / De Santi, Susan / Doraiswamy, P Murali / Petrella, Jeffrey R / Coleman, R Edward / Arnold, Steven E / Karlawish, Jason H / Wolk, David / Smith, Charles D / Jicha, Greg / Hardy, Peter / Lopez, Oscar L / Oakley, MaryAnn / Simpson, Donna M / Porsteinsson, Anton P / Goldstein, Bonnie S / Martin, Kim / Makino, Kelly M / Ismail, M Saleem / Brand, Connie / Mulnard, Ruth A / Thai, Gaby / Mc-Adams-Ortiz, Catherine / Womack, Kyle / Mathews, Dana / Quiceno, Mary / Diaz-Arrastia, Ramon / King, Richard / Weiner, Myron / Martin-Cook, Kristen / DeVous, Michael / Levey, Allan I / Lah, James J / Cellar, Janet S / Burns, Jeffrey M / Anderson, Heather S / Swerdlow, Russell H / Apostolova, Liana / Lu, Po H / Bartzokis, George / Silverman, Daniel H S / Graff-Radford, Neill R / Parfitt, Francine / Johnson, Heather / Farlow, Martin R / Hake, Ann Marie / Matthews, Brandy R / Herring, Scott / van Dyck, Christopher H / Carson, Richard E / MacAvoy, Martha G / Chertkow, Howard / Bergman, Howard / Hosein, Chris / Black, Sandra / Stefanovic, Bojana / Caldwell, Curtis / Ging-Yuek / Hsiung, Robin / Feldman, Howard / Mudge, Benita / Assaly, Michele / Kertesz, Andrew / Rogers, John / Trost, Dick / Bernick, Charles / Munic, Donna / Kerwin, Diana / Mesulam, Marek-Marsel / Lipowski, Kristina / Wu, Chuang-Kuo / Johnson, Nancy / Sadowsky, Carl / Martinez, Walter / Villena, Teresa / Turner, Raymond Scott / Johnson, Kathleen / Reynolds, Brigid / Sperling, Reisa A / Johnson, Keith A / Marshall, Gad / Frey, Meghan / Yesavage, Jerome / Taylor, Joy L / Lane, Barton / Rosen, Allyson / Tinklenberg, Jared / Sabbagh, Marwan / Belden, Christine / Jacobson, Sandra / Kowall, Neil / Killiany, Ronald / Budson, Andrew E / Norbash, Alexander / Johnson, Patricia Lynn / Obisesan, Thomas O / Wolday, Saba / Bwayo, Salome K / Lerner, Alan / Hudson, Leon / Ogrocki, Paula / Fletcher, Evan / Carmichael, Owen / Olichney, John / Kittur, Smita / Borrie, Michael / Lee, T-Y / Bartha, Rob / Johnson, Sterling / Asthana, Sanjay / Carlsson, Cynthia M / Potkin, Steven G / Preda, Adrian / Nguyen, Dana / Tariot, Pierre / Fleisher, Adam / Reeder, Stephanie / Bates, Vernice / Capote, Horacio / Rainka, Michelle / Scharre, Douglas W / Kataki, Maria / Zimmerman, Earl A / Celmins, Dzintra / Brown, Alice D / Pearlson, Godfrey D / Blank, Karen / Anderson, Karen / Santulli, Robert B / Schwartz, Eben S / Sink, Kaycee M / Williamson, Jeff D / Garg, Pradeep / Watkins, Franklin / Ott, Brian R / Querfurth, Henry / Tremont, Geoffrey / Salloway, Stephen / Malloy, Paul / Correia, Stephen / Rosen, Howard J / Miller, Bruce L / Mintzer, Jacobo / Longmire, Crystal Flynn / Spicer, Kenneth / Finger, Elizabether / Rachinsky, Irina / Drost, Dick / Jernigan, Terry / McCabe, Connor / Grant, Ellen / Ernst, Thomas / Kuperman, Josh / Chung, Yoon / Murray, Sarah / Bloss, Cinnamon / Darst, Burcu / Pritchett, Lexi / Saito, Ashley / Amaral, David / DiNino, Mishaela / Eyngorina, Bella / Sowell, Elizabeth / Houston, Suzanne / Soderberg, Lindsay / Kaufmann, Walter / van Zijl, Peter / Rizzo-Busack, Hilda / Javid, Mohsin / Mehta, Natasha / Ruberry, Erika / Powers, Alisa / Rosen, Bruce / Gebhard, Nitzah / Manigan, Holly / Frazier, Jean / Kennedy, David / Yakutis, Lauren / Hill, Michael / Gruen, Jeffrey / Bosson-Heenan, Joan / Carlson, Heatherly

    Proceedings of the National Academy of Sciences of the United States of America

    2012  Volume 109, Issue 10, Page(s) 3985–3990

    Abstract: Visual cortical surface area varies two- to threefold between human individuals, is highly heritable, and has been correlated with visual acuity and visual perception. However, it is still largely unknown what specific genetic and environmental factors ... ...

    Abstract Visual cortical surface area varies two- to threefold between human individuals, is highly heritable, and has been correlated with visual acuity and visual perception. However, it is still largely unknown what specific genetic and environmental factors contribute to normal variation in the area of visual cortex. To identify SNPs associated with the proportional surface area of visual cortex, we performed a genome-wide association study followed by replication in two independent cohorts. We identified one SNP (rs6116869) that replicated in both cohorts and had genome-wide significant association (P(combined) = 3.2 × 10(-8)). Furthermore, a metaanalysis of imputed SNPs in this genomic region identified a more significantly associated SNP (rs238295; P = 6.5 × 10(-9)) that was in strong linkage disequilibrium with rs6116869. These SNPs are located within 4 kb of the 5' UTR of GPCPD1, glycerophosphocholine phosphodiesterase GDE1 homolog (Saccharomyces cerevisiae), which in humans, is more highly expressed in occipital cortex compared with the remainder of cortex than 99.9% of genes genome-wide. Based on these findings, we conclude that this common genetic variation contributes to the proportional area of human visual cortex. We suggest that identifying genes that contribute to normal cortical architecture provides a first step to understanding genetic mechanisms that underlie visual perception.
    MeSH term(s) Adolescent ; Adult ; Aged ; Brain/pathology ; Brain Mapping/methods ; Cohort Studies ; Diagnostic Imaging/methods ; Female ; Genetic Variation ; Genome-Wide Association Study ; Genomics ; Genotype ; Humans ; Male ; Middle Aged ; Models, Genetic ; Phosphoric Diester Hydrolases/genetics ; Polymorphism, Single Nucleotide ; Saccharomyces cerevisiae/metabolism ; Visual Cortex/anatomy & histology ; Visual Cortex/pathology
    Chemical Substances Phosphoric Diester Hydrolases (EC 3.1.4.-) ; glycerophosphocholine phosphodiesterase (EC 3.1.4.2) ; glycerophosphodiester phosphodiesterase (EC 3.1.4.46)
    Language English
    Publishing date 2012-02-16
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, P.H.S.
    ZDB-ID 209104-5
    ISSN 1091-6490 ; 0027-8424
    ISSN (online) 1091-6490
    ISSN 0027-8424
    DOI 10.1073/pnas.1105829109
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top